Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

Drucebo effect – the challenge we should all definitely face!

(2021) Maciej Banach et al.   Archives of Medical Science

Lipid-lowering therapies: Better together

(2021) Maciej Banach et al.   ATHEROSCLEROSIS

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study

(2021) Daniel Gaudet et al.   European Journal of Preventive Cardiology

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

(2020) Jan Borén et al.   EUROPEAN HEART JOURNAL

Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project

(2020) Emanuele Barbato et al.   EUROPEAN HEART JOURNAL

LDL-C: lower is better for longer—even at low risk

(2020) Peter E. Penson et al.   BMC Medicine

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

(2020) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

(2020) Barbara Cybulska et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go

(2020) Maciej Banach et al.   JAMA Network Open

Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit

(2019) Jennifer G. Robinson et al.   Journal of Clinical Lipidology

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

(2019) Guy De Backer et al.   ATHEROSCLEROSIS

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

(2019) P Penson et al.   EUROPEAN HEART JOURNAL

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

European Society of Cardiology: Cardiovascular Disease Statistics 2019

(2019) Adam Timmis et al.   EUROPEAN HEART JOURNAL

Statin loading in cardiovascular surgery

(2018) Niki Katsiki et al.   CURRENT OPINION IN CARDIOLOGY

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?

(2018) Maciej Banach et al.   CARDIOVASCULAR RESEARCH

Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?

(2018) Beata Franczyk et al.   EXPERT OPINION ON PHARMACOTHERAPY

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions

(2018) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

(2017) Maria-Corina Serban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes

(2017) Baris Gencer et al.   Journal of the American Heart Association

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

(2016) Maciej Banach et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Determining When to Add Nonstatin Therapy

(2016) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction

(2016) Faraz Kureshi et al.   JAMA Cardiology

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Adverse Effects of Statins - Myths and Reality

(2015) Iveta Simic et al.   CURRENT PHARMACEUTICAL DESIGN

Resistance and intolerance to statins

(2014) Ž. Reiner   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES